**eTable 14. Checklist of the official extension of the Consolidated Standards of Reporting Trials 2010 Statement (CONSORT-SPI).**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Section** | **Item #** | **Consort-Spi 2010** | **Consort-Spi**  **2018** | **Reported On Page #** |
| **Title And Abstract** | | | | |
|  | 1a | Identification as a randomised trial in the title§ |  | 1 |
|  | 1b | Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for Abstracts)§ | Refer to CONSORT extension for social and psychological intervention trial abstracts | 2 |
| **Introduction** | | | | |
| Background and  Objectives | 2a | Scientific background and explanation of rationale § |  | 3 – 4 |
| 2b | Specific objectives or hypotheses § | If pre-specified, how the intervention was hypothesied to work | 4 |
| **Methods** | | | | |
| Trial Design | 3a | Describe of trial design (such as parallel, factorial), including allocation ratio § | If the unit of random assignment is not the individual, please refer to CONSORT for Cluster Randomized Trials | 6 |
| 3b | Important changes to methods after trial commencement (such as eligibility criteria), with reasons |  | Not applicable |
| Participants | 4a | Eligibility criteria for participants§ | When applicable, eligibility criteria for settings and those delivering the interventions | 4 |
| 4b | Settings and locations where the data were collected |  | 4 – 5 |
| Interventions | 5 | The interventions for each group with sufficient details to allow replication, including how and when they are actually administered § |  | 5 |
| 5a |  | Extent to which interventions were actually delivered by providers and taken up by participants as planned | 5 - 6 |
| 5b |  | Where other informational materials about delivering the intervention can be accessed | Supplement 2, 8 – 10 |
| 5c |  | When applicable, how intervention providers were assigned to each group | Not applicable |
| Outcomes | 6a | Completely defined pre-specified outcomes, including how and when they were assessed§ |  | 6 – 7 |
| 6b | Any changes to trial outcomes after the trial commenced, with reasons |  | Not applicable |
| Sample Size | 7a | How sample size was determined§ |  | 6 |
| 7b | When applicable, explanation of any interim analyses and stopping guidelines |  | Not applicable since no interim analyses planned or conducted |
| **Randomisation** | | | | |
| Sequence  generation | 8a | Method used to generate the random allocation sequence |  | 6 |
| 8b | Type of randomisation; detail of any restriction (such as blocking and block size)§ |  | 6 |
| Allocation concealment mechanism | 9 | Mechanism used to implement the random allocation sequence, describing any steps taken to conceal the sequence until interventions were assigned§ |  | 6 |
| Implementation | 10 | Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions§ |  | 6 |
| Awareness of assignment | 11a | Who was aware of intervention assignment after allocation (for example, participants, providers, those assessing outcomes), and how any masking was done |  | 4 |
| 11b | If relevant, description of the similarity of interventions |  | 5 |
| Analytical  methods | 12a | Statistical methods used to compare group outcomes§ | How missing data were handled, with details of any imputation method | 7 |
| 12b | Methods for additional analyses, such as subgroup analyses, adjusted analyses, and process evaluations |  | Statistical Analysis Plan, 9 – 12 |
| **Results** | | | | |
| Participant flow (a diagram is strongly recommended) | 13a | For each group, the numbers randomly assigned, receiving the intended intervention, and analysed for the outcomes§ | Where possible, the number approached, screened, and eligible prior to random assignment, with reasons for non-enrolment | 8, Figure 1 |
| 13b | For each group, losses and exclusions after randomisation, together with reasons§ |  | 8, Figure 1 |
| Recruitment | 14a | Dates defining the periods of recruitment and follow-up |  | 4 |
| 14b | Why the trial ended or was stopped |  | 4 |
| Baseline data | 15 | A table showing baseline characteristics for each group§ | Include socioeconomic variables where applicable | 24 |
| Numbers analysed | 16 | For each group, number included in each analysis and whether the analysis was by original assigned groups§ |  | 8 |
| Outcomes and estimation | 17a | For each outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)§ | Indicate availability of trial data | 8 – 10, 26 – 32 |
| 17b | For binary outcomes, the presentation of both absolute and relative effect sizes is recommended |  | 8 – 10, 26 – 32 |
| Ancillary analyses | 18 | Results of any other analyses performed, including subgroup analyses, adjusted analyses, and process evaluations, distinguishing pre-specified from exploratory |  | Not applicable |
| Harms | 19 | All important harms or unintended effects in each group (for specific guidance see CONSORT for Harms) |  | 9 |
| **Discussion** | | | | |
| Limitations | 20 | Summarize the main results (including an overview of concepts, themes, and types of evidence available), link to the review questions and objectives, and consider the relevance to key groups. | Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses | 10 – 14 |
| Generalisability | 21 | Discuss the limitations of the scoping review process. | Generalizability (external validity, applicability) of the trial findings§ | 12 |
| Interpretation | 22 | Provide a general interpretation of the results with respect to the review questions and objectives, as well as potential implications and/or next steps. | Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence | 10 – 14 |
| **Important Information** | | | | |
| Registration | 23 | Registration number and name of trial registry |  | 2, 4 |
| Protocol | 24 | Where the full trial protocol can be accessed, if available |  | 2, 4 |
| Declaration of Interests | 25 | Sources of funding and other support; role of funders | Declaration of any other potential interests | 15 |
| Stakeholder investments | 26a |  | Any involvement of the intervention developer in the design, conduct, analysis, or reporting of the trial | Not applicable |
| 26b |  | Other stakeholder involvement in trial design, conduct, or analyses | Not applicable |
| 26c |  | Incentives offered as part of the trial | 4 |